๊ฐ€์ž… ํ›„ ์ดˆ๋Œ€ ๋งํฌ๋ฅผ ๊ณต์œ ํ•˜๋ฉด ๋™์˜์ƒ ์žฌ์ƒ ๋ฐ ์ดˆ๋Œ€ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

Hardik Shah
@AIStockSavvy
Software Developer | AI-Powered News Insights, Earnings Reports and Analyst Ratings | Follow for Savvy Insights, Not Advice #AI# #StockMarket#
๊ฐ€์ž… September 2009
1.2K ํŒ”๋กœ์ž‰ ์ค‘    39K ํŒฌ
$HIMS | BofA Securities maintains ๐๐ž๐ฎ๐ญ๐ซ๐š๐ฅ on ๐‡๐ข๐ฆ๐ฌ & ๐‡๐ž๐ซ๐ฌ, ๐ซ๐š๐ข๐ฌ๐ž๐ฌ ๐๐“ ๐ญ๐จ $๐Ÿ‘๐Ÿ” ๐Ÿ๐ซ๐จ๐ฆ $๐Ÿ๐Ÿ“, 'This update is negative for the HIMS' Analyst sees a recent FDA update as negative for HIMS's peptide optionality narrative, lowering the probability of a clear legal pathway for compounding.
๋” ๋ณด๊ธฐ
$HIMS | BofA Global Research ๐ซ๐š๐ข๐ฌ๐ž๐ฌ ๐๐“ on ๐‡๐ข๐ฆ๐ฌ & ๐‡๐ž๐ซ๐ฌ to $๐Ÿ‘๐Ÿ” from $๐Ÿ๐Ÿ“, maintains Rating